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 The Rotavirus vaccination programme for infants <5 years old in Scotland was associated 7 
with a reduction in healthcare resource utilisation. 8 
 The Rotavirus vaccination programme was associated with a reduction in healthcare 9 
resource costs of 38% (approximately £595,000 per 100,000 infants under five years old) 10 
before accounting for the cost of the programme. 11 
 83% of the reduction in costs associated with rotavirus-related resources use came from 12 
reduced hospitalisations. 13 
 Based on our assumed costing of vaccine at £23.91 per single dose the cost of the 14 
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£435,000 per 100,000 infants under five years old. 17 
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Abstract 24 
Aim: In July 2013, the Scottish Government introduced a rotavirus vaccination programme into the 25 
childhood immunisation schedule. The aim of this research was to estimate the cost impact of this 26 
programme.  Methods: Data for rotavirus-related resource use were identified including laboratory 27 
reports, hospitalisations, attendances at Accident and Emergency Departments, general practice 28 
consultations, calls to the National Health Service telephone helpline and prescriptions for common 29 
rehydration treatments.  We used an interrupted time series analysis approach to assess the impact 30 
on resource utilisation in all categories.  Appropriate costs were added to the models and predicted 31 
pre and post vaccination mean annual costs were estimated. The cost of the vaccination programme 32 
was estimated using costs from the literature.  Results: The vaccination programme was associated 33 
with a reduction in utilisation in all measured healthcare resource categories.  These reductions 34 
were all statistically significant (at the 95% level) with p-values less than 0.001.  Reductions ranged 35 
from 18% in calls to NHS24 to 73% in positive laboratory reports.  The vaccination programme was 36 
associated with a reduction in annual healthcare resource costs of 38% (£595,000 per 100,000 37 
infants under five years old) in our measured categories (including £495,000 from a reduction in 38 
hospital stays).  The annual overall cost-impact of the rotavirus vaccination programme (the cost of 39 
delivering the programme minus the reduction in resource costs) was estimated at approximately 40 
£435,000 per 100,000 infants under 5 years old.  Conclusion: The rotavirus vaccination programme 41 
was associated with a reduction in all measured categories of rotavirus-related resource use by 42 
infants under 5 years old. 43 
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1. Introduction 45 
Rotavirus is the leading cause of severe gastroenteritis in infants worldwide and results in 46 
approximately 500,000 deaths annually in infants under the age of 5 years [1]. Unlike in the 47 
developing world, rotavirus rarely causes mortality in the UK, however infection results in a high 48 
number of hospital admissions for severe dehydration in infants [1] and impacts on health related 49 
quality of life (HRQOL) [2]. It has been estimated that rotavirus causes around 45% of 50 
hospitalisations for acute gastroenteritis in infants under the age of 5 years [2]. In addition, 51 
infections resulting in hospitalisation represent only a fraction of cases that occur in the community 52 
which cause substantial morbidity with consequent impact on healthcare providers such as general 53 
practitioners (GPs) and out-of-hours services. 54 
In July 2013, the Scottish Government, along with the rest of the UK, introduced the GlaxoSmithKline 55 
(GSK) vaccine Rotarix® [3]. The vaccine was made available to all infants born in Scotland on or after 56 
May 1st 2013 and delivered as part of the routine childhood immunisation programme. Over the first 57 
evaluation quarter 1st July – 30th September 2014, uptake of the rotavirus vaccine was 93% [4]. The 58 
vaccine was made available to all infants at age 8 weeks (1st dose) and again at 12 weeks (2nd dose).  59 
Routine surveillance carried out by Health Protection Scotland (HPS) found evidence of substantial 60 
reductions in rotavirus-related burden of disease in infants [5] similar to that reported elsewhere [6-61 
10]. The aim of this research was to estimate the cost-impact of the rotavirus vaccination 62 
programme in Scotland, based on a retrospective analysis of routinely collected data on actual 63 
healthcare utilisation. 64 
2. Results 65 
2.1 Overall cost-impact 66 
Table 1 shows the overall cost-impact of the rotavirus vaccination programme.  Results are reported 67 
in terms of the cost of the programme, the monetary value of the reduction in resource use pre-and 68 
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post-vaccination period, and the difference between the cost of the programme and the value of the 69 
reduction in resource use is estimated as the overall cost-impact of the programme. 70 
[INSERT TABLE 1] 71 
2.2 Cost of vaccination programme 72 
Based on the actual number of infants who received the vaccine over the evaluation period 1st July-73 
30th September 2013, it was calculated that 18,575 infants received the vaccination in 2013, per 74 
100,000 infants <5 years old living in Scotland (note: the vaccine uptake rate was 92.7% however 75 
rates per 100,000 are calculated over the entire relevant population of infants <5 years old) [4]. This 76 
figure is multiplied by the vaccine cost per 2 doses. On the assumption of a vaccine price of £23.91 77 
per dose [11], we estimated a total vaccine cost of £888,278 per 100,000 infants <5 years old in 78 
Scotland in 2013/14. The additional administrative payment made to GPs of £7.67 per infant (per 79 
two doses) [4] equates to £142,474 per 100,000 infants <5 years old in Scotland.  Taken together, 80 
this indicates that the cost of the vaccination programme was £1,030,751 per 100,000 infants <5 81 
years old in Scotland. 82 
2.3 Sensitivity analysis 83 
We undertook sensitivity analysis to estimate the impact of alternative vaccine prices on the overall 84 
cost of the vaccination programme. Table 2 presents the results based on a 50% increase or 85 
reduction from the price given in the base case. The results suggest that the overall cost of the 86 
programme is highly sensitive to the price of the vaccine. 87 
[INSERT TABLE 2] 88 
2.3 Reduction in rotavirus-related resource use 89 
Table 3 shows the reduction in rotavirus-related resource use associated with infants <5 years old 90 
for the mean year pre- and post-vaccination programme.  Data is presented as incident rate ratios 91 
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(IRRs) which can be interpreted as representing a percentage reduction in resource use.  For 92 
example, the IRR associated with vaccination for laboratory reports is 0.273 which equates to a 93 
reduction of 72.7% (1-0.273 expressed as a percentage).  Also presented are the model predicted 94 
pre and post vaccination annual number of events, the 95% confidence intervals (CIs) and the p-95 
value associated with the vaccination variable in the model.  For each resource use appropriate cost 96 
data were attached and the resulting annual costs per 100,000 infants <5 are presented. 97 
Table 3: Adjust incidence rate ratios (IRRs) for the association between vaccination and 98 
rotavirus-related annual events and costs, for infants <5 years old in Scotland 99 
 100 
[INSERT TABLE 3] 101 
 102 
Notes: CI – confidence intervals. IRR–Incidence Rate Ratio.  An IRR below 1 indicates a reduction in events and 103 
costs associated with the vaccination programme. P-value is a measure of statistical significance and a result 104 
under 0.05 is considered statistically significant for the purposes of this study. All models were adjusted for 105 
seasonality and underlying trend. The mean costs are estimated by applying a unit cost to the event rates 106 
predicted by the model.   107 
 108 
All measured resource categories showed statistically significant reductions associated with the 109 
introduction of the rotavirus vaccination programme.  These varied in magnitude according to the 110 
resource category with laboratory reports showing the highest reduction of 73% (IRR 0.273, 111 
p<0.001) and the smallest reduction of 17% in calls to NHS24 (IRR 0.826, p<0.001).  Table 3 also 112 
presents the cost difference estimated from the predicted pre and post vaccination mean costs.  The 113 
reduction in hospital stays forms the largest part of the cost difference.  Figures 1 and 2 present the 114 
actual and predicted counts for laboratory reports and hospital stays respectively.  Equivalent figures 115 
for the other resource categories are presented in the Appendix.  These figures were selected for 116 
presentation in the main body of the article as they illustrate the model fit achieved in the most 117 
specific measure of rotavirus (positive laboratory reports) and the largest cost category (hospital 118 
stays). 119 
Figure 1: Positive laboratory reports for rotavirus (weekly rates per 100,000), for infants <5 120 
years old in Scotland – 2009 to 2015. 121 
 122 
[INSERT FIGURE 1] 123 
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Notes: R2=0.86. Dashed line represents introduction of vaccination programme 124 
Figure 2: Hospital length of stay for rotavirus (weekly rates per 100,000), for infants <5 years 125 
old in Scotland – 2010 to 2015. 126 
 127 
[INSERT FIGURE 2] 128 
Notes: R2=0.83. Dashed line represents introduction of vaccination programme 129 
3. Discussion 130 
Our study found statistically significant reductions in all rotavirus-related health-care resource 131 
categories examined following the introduction of the vaccination programme.  However, the range 132 
of the reductions varied from 17% to 73%.  The size of the reduction is driven by the ability of the 133 
data source to accurately capture cases of rotavirus.  The highest reduction was found in the most 134 
specific data source, positive laboratory reports and the lowest in the least specific areas of NHS24 135 
calls and prescriptions for rehydration treatments.  We found a 40% reduction in hospital stays, 136 
which are the main cost driver among health-care resource categories.  137 
Our findings are in line with the extensive literature across diverse geographies finding that the 138 
introduction of a rotavirus vaccination programme leads to reductions in a broad range of health-139 
care resource categories [16, 17].  Prior to the introduction of the rotavirus vaccination programme, 140 
the Scottish Government predicted that such a programme could reduce the number of rotavirus-141 
related hospital stays by approximately 70% [12]. Forrest et al (2017) found a reduction of 85% and 142 
91% in rotavirus related admissions and bed-days, respectively, in a paediatric hospital setting in 143 
Lothian, Scotland [13].  This study used a highly specific definition of rotavirus-based admissions 144 
based on positive laboratory reports so is comparable with the 73% reduction suggested by our 145 
study.  In undertaking this study, we gave much consideration to the issue of how best to capture 146 
the impact of rotavirus on hospital resources. When we considered the changes in solely those 147 
hospital admissions and bed-days which were coded for rotavirus specific (ICD10 code “A080” in 148 
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either 1st and 2nd diagnostic position), we observed higher reductions in hospital admissions for 149 
rotavirus and rotavirus-related hospital stays similar to the reductions found by Forrest et al [12].  150 
However, many hospital admissions relating to rotavirus are coded as generic viral enteritis, 151 
particularly when specific organism testing is not required for clinical management. As the aim of 152 
this study is to estimate the cost impact we chose to increase the sensitivity of our measure by 153 
including viral enteritis unspecified (possible rotavirus) “A083”, “A084” and “A085” as well as the 154 
specific rotavirus code “A080”.  This would have the effect of increasing the volume of cases in both 155 
the pre and post vaccination periods as well as reducing the percentage differences between the 156 
periods.  It is likely that using these codes will miss a proportion of rotavirus cases as they are likely 157 
to be coded under general acute gastroenteritis codes [13].  Our finding of a 40% reduction in 158 
hospital admissions is in line with a the 44% reduction found in  a study of five local authority areas 159 
in Merseyside, England over the period 2013-2016 (consisting of five hospitals with emergency and 160 
secondary care facilities and a paediatric hospital)[14].  . 161 
We found that the impact of the vaccine in primary care was lower than that predicted by Jit et al 162 
(2007), with a substantial proportion of overall reduction in healthcare cost due to a decrease in GP 163 
consultations [11]. Data were available on consultations for diarrhoea, vomiting and all 164 
gastrointestinal illness, however due to possible double counting and for consistency with other data 165 
analysed for this study, we decided only to include the impact from consultations for diarrhoea. This 166 
may therefore represent an underestimate, which may explain the 32% reduction in prescriptions 167 
during the rotavirus season, despite only a 16% reduction in consultations. Lack of adherence to the 168 
use of appropriate Read codes may also help to explain this underestimate. 169 
The impact of childhood rotavirus infection and the vaccine on nonmedical costs was not included in 170 
this study, however it is likely that there are significant costs associated with productivity loss (or 171 
“time-off” work) of the parent(s). Different studies give different estimates of the number of work 172 
days lost – typically ranging from around two to five days [15]. The typical UK worker earns a median 173 
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daily wage of £103.6 [16]. Hence, 2 days (5 days) forgone work on behalf of the caregiver results in 174 
£207.2 (£518) in lost earnings per childhood rotavirus case. Some estimates suggest that the loss in 175 
productivity to the economy is the difference between a rotavirus vaccination programme being, not 176 
only cost-effective, but cost saving in the UK [17].  177 
This study only considers costs and does not value the improved quality of life which a reduction in 178 
rotavirus incidence would deliver.  Jit and Edmunds (2007) report a quality of life (QALY) loss due to 179 
rotavirus of 0.0022 for a child and 0.00184 for an adult per case of rotavirus [11]. In our study, there 180 
was a mean of 472 laboratory confirmed cases of rotavirus pre-vaccination programme, compared 181 
with 110 cases post- vaccination programme, per 100,000 infants <5 in Scotland. If we use this as a 182 
proxy for the mean number of rotavirus cases pre- and post-vaccination, then we estimate the QALY 183 
loss averted per family (2 adults, 1 infant) as 2.13 QALYs per 100,000 infants <5 years old in Scotland 184 
between the mean year pre-and post-vaccination period. 185 
Since completion of our analysis, the first full year of data became available for calendar year 2015 186 
(infants born Jan-Dec 2014). These indicate 53,013 infants (18,141 infants per 100,000) received 187 
rotavirus vaccine in 2015. This is comparable with the estimate used in our analysis (18,575 infants, 188 
per 100,000). 189 
Strengths and limitations 190 
At time of publication, this is the only study the authors are aware of which attempts to estimate the 191 
cost-impact of the rotavirus vaccination programme for the whole of Scotland, based on 192 
observational data. 193 
The challenge with using indicators of gastrointestinal illness such as reporting of symptoms of 194 
diarrhoea as a proxy for rotavirus is that it also captures changes in the prevalence of other 195 
gastrointestinal illnesses unrelated to rotavirus. As a result, there are uncertainties in the estimates 196 
of resource use both pre and post vaccination and these differ depending upon the type of resource-197 
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use considered.  In comparing our results with other studies it is, therefore, important to note the 198 
precise definitions included in the analysis. 199 
We obtained data on the number of prescriptions made per day per patient population, however, 200 
we did not have a further breakdown of composition of these prescriptions (i.e. which hydration 201 
drugs were given). Hence, it was not possible to calculate the change in mean prescriptions and then 202 
attach unit costs. Rather, we calculated the change in the mean gross cost of prescriptions pre-and 203 
post-vaccination programme. A detailed breakdown of the prescriptions given would have provided 204 
a more accurate estimate of the cost-impact, however it is not clear whether an absence of this 205 
breakdown suggests an over-or underestimate of the overall cost-impact. The data we obtained was 206 
based on prescriptions for rotavirus in primary care. However, there is the possibility that these 207 
prescriptions, which are mainly rehydration drugs, could have been prescribed for alternative 208 
conditions requiring rehydration.  209 
Due to duplication concerns, it was not possible to use calls relating to vomiting and diarrhoea, 210 
combined, from NHS24 data. Hence, data on calls citing diarrhoea in infants <1 year old and <5 years 211 
old were used as a proxy for rotavirus. It is acknowledged that this is likely to be an underestimate of 212 
the true total cost associated with NHS24.  Similarly, for duplication concerns, only GP consultations 213 
for diarrhoea were included. This is also likely to represent a considerable underestimate of the cost. 214 
The overall cost-impact of the vaccination programme was highly sensitive to the cost of the vaccine, 215 
which we were not able to confirm.  Our analysis relies on an estimate from the literature which we 216 
varied in sensitivity analysis.  217 
4. Conclusion 218 
In this study we have estimated the mean change in rotavirus-related resource use before-and-after 219 
the introduction of the Scottish Government’s rotavirus vaccination programme in 2013. In doing so, 220 
we have observed reductions in the burden placed on rotavirus-related; laboratory reports; 221 
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hospitalisations; GP consultations; A&E attendances; and NHS24 calls. Our analysis showed a 222 
reduction in the mean number of rotavirus-related hospital bed-days of 40%. This reduction 223 
accounted for 83% of the overall cost reduction associated with the implementation of the rotavirus 224 
vaccination programme. This study found that the overall cost impact of the rotavirus vaccination 225 
programme (that is, the cost of delivering the programme minus the reduction in resource costs) 226 
was £435,000 increase (2013 prices) per annum per 100,000 infants <5 years.  227 
5. Methods 228 
5.1 Statistical analysis 229 
In line with previous research [18] and European Centre for Disease Prevention and Control (ECDC) 230 
[19] guidance, this study adopted a “before and after” approach with the pre-vaccination period 231 
serving as a reference point from which to compare the post-vaccination period.  232 
This study defined the net cost-impact of the programme as being the cost of the vaccination 233 
programme minus cost reductions in resource use. As such, the net cost-impact was defined as 234 
follows: 235 
Net cost impact = (cost of vaccine + administration payment) – (cost reductions from lab reports, 236 
hospitalisations, A&E attendances, GP consultations, prescriptions and NHS24 calls). 237 
To compare the impact of the rotavirus vaccination programme, in terms of the change in resource 238 
use and cost-impact, we used an interrupted time series analysis [20]. 239 
To estimate the overall cost-impact of the rotavirus vaccination programme, we first estimated the 240 
rotavirus-related resource utilisation for each resource pre- and post-vaccination programme, in 241 
units determined by how the data were collected (i.e. resource use per week or per month).  We 242 
attached unit costs to resource use to estimate the cost of this resource over each time period for 243 
which the data were collected.  Mean resource use in the pre-and post-vaccination periods were 244 
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estimated using a range of modelling approaches.  We selected a Generalised Linear Model (GLM) 245 
with a Poisson family and log link as this reduced autocorrelation and provided the best model fit. 246 
We assessed goodness of fit of alternative models using the Akaike and Bayesian Information 247 
Criteria [21]  Underlying trend was accounted for within the regression framework and seasonality 248 
were modelled by including Fourier terms (sine and cosine terms) [20] and a dummy variable 249 
representing the peak rotavirus season (January-May). We also included an interaction term 250 
between the seasonality variables and the relevant period variable (week or month) to allow 251 
seasonality to vary in different time periods.  We hypothesised that the rotavirus vaccination 252 
programme would result in a permanent level change in resource use [20].  We therefore included a 253 
single binary variable to represent the intervention which was coded ‘0’ in the period prior to the 254 
vaccination programme and ‘1’ in the period following the introduction of the programme.  255 
Population data for all infants <5 years old living in Scotland over the study period were obtained 256 
from the National Records of Scotland and used as an offset variable [22]. Incidence rates per 257 
100,000 were calculated as the number of incidents (i.e. days in hospital or GP consultations) divided 258 
by the study population (number of infants <5 years old living in Scotland) per year multiplied by 259 
100,000. The same approach was used to estimate the cost of the programme, hence cost per 260 
100,000 represents the cost of providing the vaccination to eligible infants (age 8 weeks and again at 261 
12 weeks) to realise the benefits over the population of all infants <5 years.  262 
One-way sensitivity analysis was undertaken to estimate the impact on the cost of the vaccination 263 
programme of alternative vaccine prices. Vaccine price was varied +/-50% of the base case price.. 264 
The results are presented in the appendix. 265 
5.2 Perspective  266 
This study takes the perspective of the UK National Health Service (NHS) and includes resource use 267 
associated with laboratory reports, hospitalisations, A&E attendances, GP consultations, 268 
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prescriptions and NHS24 calls. This is the only study at present to take such a wide perspective in 269 
estimation of the economic benefits from a national rotavirus vaccination programme in Scotland.  270 
5.3 Measurement of resource use 271 
Data available for each resource were; 2009-2014 for laboratory reports; 2010-2014 for 272 
hospitalisations; 2010-2014 for NHS24 calls; 2010-2014 for prescriptions; 2011-2014 for A&E; and 273 
2011-2014 for GP consultations. 274 
5.3.1 Laboratory confirmed reports  275 
All laboratory confirmed cases of rotavirus infection in Scotland are reported to HPS via the 276 
Electronic Communications of Surveillance in Scotland (ECOSS) system [23]. A positive laboratory 277 
sample was detected using a real-time PCR and were only counted for the first sample from any 278 
patient episode and repeated laboratory tests for the same episode were not included. Laboratory 279 
reports for infants <5 years old in the pre-and post-vaccination years were used.  280 
5.3.2 Hospitalisation data 281 
All hospitalisations for infants <5 years were extracted using Scottish Morbidity Records (SMR01) 282 
database using predefined International Classification of Diseases 10 (ICD10) codes Rotavirus 283 
enteritis “A080” and Viral enteritis unspecified (possible rotavirus) “A083”, “A084” and “A085” [24]. 284 
This aimed to capture admissions for rotavirus, which are not laboratory confirmed due to the 285 
relatively short length of stay and which are coded under the more general term of viral enteritis. 286 
Due to concerns of possible double counting of patients only data with the relevant ICD10 code as 287 
main diagnosis were included.  288 
When a patient is discharged from hospital or transferred between hospitals, specialties or to the 289 
care of a different consultant, an episode is generated. Episode data were grouped together to 290 
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identify continuous inpatient stays (CIS) and it is this level of analysis that was used to monitor 291 
hospital admissions and length of stay in this study.  292 
5.3.3 Accident and Emergency (A&E) data 293 
Age specific monthly data on attendances at A&E data for symptoms associated with gastrointestinal 294 
illness was available from Information Services Division (ISD). These data are based on a combination 295 
of ICD10 codes and, where coding was not used, free text analysis. Data were analysed for infants 296 
aged <5 years. 297 
5.3.4 GP consultation data 298 
Data on GP consultations, who provide all primary care for infants in Scotland, recorded for all 299 
infants <5 years old for diarrhoea were obtained as the best proxy for rotavirus-related GP 300 
attendances. Weekly aggregate data are received by HPS from approximately 50% of General 301 
Practices (GP) across Scotland on the number of consultations based on defined Read codes, which 302 
are currently the standard clinical classification terminology system used in GPs in the United 303 
Kingdom [25]. Data were obtained from a broad geographical spread of Scotland and were 304 
considered representative of Scotland as a whole. Data were scaled to account for 100% of GP 305 
practices.   306 
5.3.5 NHS24 syndromic surveillance data 307 
HPS monitor trends in calls made to the NHS24 telephone helpline in Scotland. NHS24 is also the 308 
route to out-of-hours general practice care. Data gathered on the number of calls relating to 309 
vomiting and diarrhoea give an indication into the incidence of gastroenteritis in the community. 310 
Due to duplication concerns, it was not possible to use data relating to vomiting and diarrhoea 311 
combined. Hence, data on calls citing diarrhoea in infants <5 years old were used as a proxy for 312 
rotavirus. 313 
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5.3.6 Prescription data 314 
Data on rotavirus-related drug prescriptions were collected by the Prescribing Information System 315 
(PIS) provided by ISD Scotland and based on prescriptions administered in the primary care setting. 316 
Treatment for rotavirus typically involves the prescription of oral rehydration drugs. Data on 317 
prescription of the following drugs, listed in local formularies, were used as a proxy for rotavirus and 318 
viral enteritis: Dioralyte; Dioralyte Relief; Electrolade; O.R.S Oral, Peach. Data were provided in terms 319 
of the gross ingredient cost (£) per month for infants <5 years old over the period 2010-2015. Hence, 320 
change in gross cost pre-and post-vaccination were reported, rather than change in resource use 321 
(i.e. unit costs were not necessary). 322 
5.3.7 Vaccine price 323 
The Joint Committee on Vaccination and Immunisation (JCVI) carried out a review of the published 324 
literature on the cost-effectiveness of rotavirus vaccines on behalf of the Scottish Government [26]. 325 
The JCVI statement on rotavirus vaccine assumes a vaccine unit price of £35 per dose (2006 prices), 326 
based on the work of Jit & Edmunds [11]. At the price of £35 per dose, the incremental cost per 327 
QALY gained would be £61,000 and hence unlikely to be considered cost-effective. Further 328 
modelling by the authors suggested that the vaccine would have to be priced at £19 per dose for the 329 
cost of the programme to be less that £30,000 per QALY gained and hence deemed cost effective, 330 
given the current UK threshold. For this reason, we chose to assume a vaccine price of £19 per dose 331 
[11]. Inflating this to 2014 prices equates to £23.91 per dose and this was used as our base case 332 
price. Due to commercial sensitivities, there is no published price for the vaccine other than the JCVI 333 
statement. 334 
The local health board pay each relevant GP an administrative payment of £7.67 per child receiving 335 
the rotavirus vaccination (one payment for two doses)[27]. This payment was therefore included as 336 
a direct cost of providing the service. 337 
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5.3.8 Valuation of resource use  338 
All prices are expressed in 2013/14 prices and have been inflated (where necessary) using the 339 
Hospital and Community Health Services (HCHS) Index which uses an inflation rate specific to the UK 340 
health service (PSSRU, 2014).  341 
Any stool sample taken from an infant suffering from diarrhoea and vomiting would undergo a full 342 
screening for a range of gastrointestinal pathogens, rather than for one specific causative agent.  343 
Hence, the unit cost of a routine enteritis laboratory report was given by Lorgelly et al as £15.08 per 344 
report (in 2001/02 prices, £20.99 in 2013/14 prices) [28].  345 
The unit cost estimate for hospitalisations in 2013/14 was obtained from ISD. Using their new 346 
patient-level costing data, they were able to estimate the cost per day of hospital treatment for 347 
rotavirus (based on ICD10 code A080). The unit cost per day for rotavirus was estimated at £920 348 
(2013/14).  This unit cost is applied to both incidents of rotavirus coded as “rotavirus” and “viral 349 
enteritis” in SMR01 hospitalisation data.  350 
A standard unit cost of £107 per attendance at A&E was obtained from ISD’s annual Scottish Health 351 
Service Costs [29]. 352 
The unit cost of a GP consultation was obtained from the Personal Social Services Research Unit 353 
2014 publication [30]. The unit cost was £37.50, per GP visit lasting 11.7 minutes (excluding 354 
qualification costs). 355 
The unit cost per call to NHS24 was reported by Munro et al as £15 (2001 prices). Inflating this to 356 
2014, provides a unit cost of £20.88 [31]. 357 
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Highlights 6 
 The Rotavirus vaccination programme for infants <5 years old in Scotland was associated with 7 
a reduced incidence of rotavirusreduction in infants <5 years oldhealthcare resource 8 
utilisation. 9 
 The Rotavirus vaccination programme was also was associated with a reduction in healthcare 10 
resource usecosts of 38% (approximately £595,000 per 100,000 infants under five years old) 11 
before accounting for the cost of the programme. 12 
 Almost all (95%)83% of the reduction in healthcare resource usecosts associated with this 13 
vaccination programme was observed between January and Aprilrotavirus-related resources 14 
use came from reduced hospitalisations. 15 
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 Based on our assumed costing of vaccine at £23.91 per single dose the cost of the vaccination 23 
programme is estimated at approximately £1,031,000 per 100,000 infants under five years 24 
old, resulting in an overall annual cost of the programme of approximately £435,000 per 25 
100,000 infants under five years old. 26 
 27 
 28 
 29 
*corresponding author at: Health Economics and Health Technology Assessment (HEHTA), Institute of 30 
Health and Wellbeing, 1 Lilybank Gardens, University of Glasgow, United Kingdom, G12 8RZ. Email: 31 
robert.heggie@glasgow.ac.uk, Tel: +44 (0)141 330 3047 32 
Abstract 33 
Aim: In July 2013, the Scottish Government introduced a rotavirus vaccination programme into the 34 
routine childhood immunisation schedule. The aim of this research was to identify and measure the 35 
cost impact of the rotavirus vaccination programmechildhood immunisation schedule. The aim of this 36 
research was to estimate the cost impact of this programme.  Methods: Data for rotavirus-related 37 
resource use were identified including laboratory reports, hospitalisations, attendances at Accident 38 
and Emergency Departments, general practice consultations, calls to the National Health Service 39 
telephone helpline and prescriptions for common rehydration treatments.  We used an interrupted 40 
time series analysis approach to assess the impact on resource utilisation in all categories.  41 
Appropriate costs were added to the models and predicted pre and post vaccination mean annual 42 
costs were estimated. The cost of the vaccination programme was estimated using costs from the 43 
literature.  Results: The vaccination programme was associated with a reduction in utilisation in all 44 
measured healthcare resource categories.  These reductions were all statistically significant (at the 45 
95% level) with p-values less than 0.001.  Reductions ranged from 18% in calls to NHS24 to 73% in 46 
positive laboratory reports.  The vaccination programme was associated with a reduction in annual 47 
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healthcare resource costs of 38% (£595,000 per 100,000 infants under five years old) in our measured 48 
categories (including £495,000 from a reduction in hospital stays).  The annual overall cost-impact of 49 
the rotavirus vaccination programme (the cost of delivering the programme minus the reduction in 50 
resource costs) was estimated at approximately £435,000 per 100,000 infants under 5 years old.  51 
Conclusion: The rotavirus vaccination programme was associated with a reduction in all measured 52 
categories of rotavirus-related resource use by infants under 5 years old. 53 
Methods: Data from a range of sources representing healthcare utilisation across the patient 54 
pathway were identified, measured and valued. These included data on laboratory confirmed 55 
reports of rotavirus, hospitalisations for rotavirus and viral enteritis and attendances at A&E. 56 
Additionally surrogate markers of rotavirus infection were used to identify and measure vaccine 57 
impact in the community, specifically general practice consultations and calls to the National Health 58 
Service telephone helpline in Scotland, NHS24 and prescribing data for common rehydration 59 
treatments. In line with previous research and European Centre for Disease Prevention and Control 60 
(ECDC) guidance, this study adopted a “before and after” methodology. Based on multiple years of 61 
resources use, we estimated resource use in a “mean year” before and after the vaccination 62 
programme for all infants <5 years old living in Scotland. We investigated these changes annually 63 
and over the “rotavirus season”. 64 
Results: The overall cost-impact of the rotavirus vaccination programme (that is, the cost of 65 
delivering the programme minus the reduction in resource costs) was £633,499 (2013/14 prices) per 66 
mean year, per 100,000 infants <5 years old living in Scotland. Considering only the rotavirus season, 67 
we find that the total cost impact of the vaccination programme was £653,354 per mean year. 68 
Conclusion: The rotavirus vaccination programme in Scotland cost approximately £1,030,751 and 69 
was associated with a significant reduction in rotavirus-related resource use and health service costs 70 
of approximately £397,458, per 100,000 infants <5 years old living in Scotland.  71 
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 73 
2.1 Background 74 
  75 
  
1. Introduction 76 
Rotavirus is the leading cause of severe gastroenteritis in infants worldwide and results in 77 
approximately 500,000 deaths annually in children <5 yrs old [1]. Unlike in the developing world, 78 
rotavirus rarely causes mortality in the UK,  however infection results in a significantinfants under the 79 
age of 5 years [1]. Unlike in the developing world, rotavirus rarely causes mortality in the UK, however 80 
infection results in a high number of hospital admissions for severe dehydration in infants [1] and 81 
significantly impacts on health related quality of life (HRQOL) [2].[2]. It has been estimated that 82 
rotavirus causes around 45% of hospitalisations for acute gastroenteritis in childreninfants under the 83 
age of 5 years [2]. In addition, infections resulting in hospitalisation represent only a fraction of cases 84 
that occur in the community and which cause substantial morbidity with consequent impact on 85 
healthcare providers such as general practitioners (GPs) and out-of-hours services. 86 
In July 2013, the Scottish Government, along with the rest of the UK, introduced the GlaxoSmithKline 87 
(GSK) vaccine Rotarix® [3]. The vaccine was made available to all infants born in Scotland on or after 88 
May 1st 2013 and delivered as part of the routine childhood immunisation programme. Childhood 89 
vaccine uptake is generally high in Scotland with quarterly uptake figures for children aged 12 months 90 
routinely greater than 92% [4]. The vaccine was made available to all babiesOver the first evaluation 91 
quarter 1st July – 30th September 2014, uptake of the rotavirus vaccine was 93% [4]. The vaccine was 92 
made available to all infants at age 8 weeks (1st dose) and again at 12 weeks (2nd dose).  93 
 Following this, routineRoutine surveillance carried out by Health Protection Scotland (HPS) found 94 
evidence of significantsubstantial reductions in rotavirus-related burden of disease in childreninfants 95 
[5][5] similar to that reported elsewhere [6-10][6-10]. Against this background, thisThe aim of this 96 
research was to estimate the cost-impact of the rotavirus vaccination programme onin Scotland, 97 
based on a retrospective analysis of routinely collected data on actual healthcare utilisation. 98 
2. Results 99 
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2.1 Overall cost-impact 100 
Table 1 shows the overall cost-impact of the rotavirus vaccination programme.  Results are reported 101 
in terms of the cost of the programme, the monetary value of the reduction in resource use in 102 
Scotlandpre-and post-vaccination period, and the difference between the cost of the programme and 103 
the value of the reduction in resource use is estimated as the overall cost-impact of the programme. 104 
[INSERT TABLE 1] 105 
2.2 Cost of vaccination programme 106 
Based on the actual number of infants who received the vaccine over the evaluation period 1st July-107 
30th September 2013, it was calculated that 18,575 infants received the vaccination in 2013, per 108 
100,000 infants <5 years old living in Scotland (note: the vaccine uptake rate was 92.7% however rates 109 
per 100,000 are calculated over the entire relevant population of infants <5 years old) [4]. This figure 110 
is multiplied by the vaccine cost per 2 doses. On the assumption of a vaccine price of £23.91 per dose 111 
[11], we estimated a total vaccine cost of £888,278 per 100,000 infants <5 years old in Scotland in 112 
2013/14. The additional administrative payment made to GPs of £7.67 per infant (per two doses) [4] 113 
equates to £142,474 per 100,000 infants <5 years old in Scotland.  Taken together, this indicates that 114 
the cost of the vaccination programme was £1,030,751 per 100,000 infants <5 years old in Scotland. 115 
2.3 Sensitivity analysis 116 
We undertook sensitivity analysis to estimate the impact of alternative vaccine prices on the overall 117 
cost of the vaccination programme. Table 2 presents the results based on a 50% increase or reduction 118 
from the price given in the base case. The results suggest that the overall cost of the programme is 119 
highly sensitive to the price of the vaccine. 120 
[INSERT TABLE 2] 121 
2.3 Reduction in rotavirus-related resource use 122 
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Table 3 shows the reduction in rotavirus-related resource use associated with infants <5 years old for 123 
the mean year pre- and post-vaccination programme.  Data is presented as incident rate ratios (IRRs) 124 
which can be interpreted as representing a percentage reduction in resource use.  For example, the 125 
IRR associated with vaccination for laboratory reports is 0.273 which equates to a reduction of 72.7% 126 
(1-0.273 expressed as a percentage).  Also presented are the model predicted pre and post vaccination 127 
annual number of events, the 95% confidence intervals (CIs) and the p-value associated with the 128 
vaccination variable in the model.  For each resource use appropriate cost data were attached and the 129 
resulting annual costs per 100,000 infants <5 are presented. 130 
Table 3: Adjust incidence rate ratios (IRRs) for the association between vaccination and 131 
rotavirus-related annual events and costs, for infants <5 years old in Scotland 132 
 133 
[INSERT TABLE 3] 134 
 135 
Notes: CI – confidence intervals. IRR–Incidence Rate Ratio.  An IRR below 1 indicates a reduction in events and 136 
costs associated with the vaccination programme. P-value is a measure of statistical significance and a result 137 
under 0.05 is considered statistically significant for the purposes of this study. All models were adjusted for 138 
seasonality and underlying trend. The mean costs are estimated by applying a unit cost to the event rates 139 
predicted by the model.   140 
 141 
All measured resource categories showed statistically significant reductions associated with the 142 
introduction of the rotavirus vaccination programme.  These varied in magnitude according to the 143 
resource category with laboratory reports showing the highest reduction of 73% (IRR 0.273, p<0.001) 144 
and the smallest reduction of 17% in calls to NHS24 (IRR 0.826, p<0.001).  Table 3 also presents the 145 
cost difference estimated from the predicted pre and post vaccination mean costs.  The reduction in 146 
hospital stays forms the largest part of the cost difference.  Figures 1 and 2 present the actual and 147 
predicted counts for laboratory reports and hospital stays respectively.  Equivalent figures for the 148 
other resource categories are presented in the Appendix.  These figures were selected for 149 
presentation in the main body of the article as they illustrate the model fit achieved in the most 150 
specific measure of rotavirus (positive laboratory reports) and the largest cost category (hospital 151 
stays). 152 
  
Figure 1: Positive laboratory reports for rotavirus (weekly rates per 100,000), for infants <5 153 
years old in Scotland – 2009 to 2015. 154 
 155 
[INSERT FIGURE 1] 156 
Notes: R2=0.86. Dashed line represents introduction of vaccination programme 157 
Figure 2: Hospital length of stay for rotavirus (weekly rates per 100,000), for infants <5 years 158 
old in Scotland – 2010 to 2015. 159 
 160 
[INSERT FIGURE 2] 161 
Notes: R2=0.83. Dashed line represents introduction of vaccination programme 162 
3. Discussion 163 
Our study found statistically significant reductions in all rotavirus-related health-care resource 164 
categories examined following the introduction of the vaccination programme.  However, the range 165 
of the reductions varied from 17% to 73%.  The size of the reduction is driven by the ability of the data 166 
source to accurately capture cases of rotavirus.  The highest reduction was found in the most specific 167 
data source, positive laboratory reports and the lowest in the least specific areas of NHS24 calls and 168 
prescriptions for rehydration treatments.  We found a 40% reduction in hospital stays, which are the 169 
main cost driver among health-care resource categories.  170 
Our findings are in line with the extensive literature across diverse geographies finding that the 171 
introduction of a rotavirus vaccination programme leads to reductions in a broad range of health-care 172 
resource categories [16, 17].  Prior to the introduction of the rotavirus vaccination programme, the 173 
Scottish Government predicted that such a programme could reduce the number of rotavirus-related 174 
hospital stays by approximately 70% [12]. Forrest et al (2017) found a reduction of 85% and 91% in 175 
rotavirus related admissions and bed-days, respectively, in a paediatric hospital setting in Lothian, 176 
Scotland [13].  This study used a highly specific definition of rotavirus-based admissions based on 177 
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positive laboratory reports so is comparable with the 73% reduction suggested by our study.  In 178 
undertaking this study, we gave much consideration to the issue of how best to capture the impact of 179 
rotavirus on hospital resources. When we considered the changes in solely those hospital admissions 180 
and bed-days which were coded for rotavirus specific (ICD10 code “A080” in either 1st and 2nd 181 
diagnostic position), we observed higher reductions in hospital admissions for rotavirus and rotavirus-182 
related hospital stays similar to the reductions found by Forrest et al [12].  However, many hospital 183 
admissions relating to rotavirus are coded as generic viral enteritis, particularly when specific 184 
organism testing is not required for clinical management. As the aim of this study is to estimate the 185 
cost impact we chose to increase the sensitivity of our measure by including viral enteritis unspecified 186 
(possible rotavirus) “A083”, “A084” and “A085” as well as the specific rotavirus code “A080”.  This 187 
would have the effect of increasing the volume of cases in both the pre and post vaccination periods 188 
as well as reducing the percentage differences between the periods.  It is likely that using these codes 189 
will miss a proportion of rotavirus cases as they are likely to be coded under general acute 190 
gastroenteritis codes [13].  Our finding of a 40% reduction in hospital admissions is in line with a the 191 
44% reduction found in  a study of five local authority areas in Merseyside, England over the period 192 
2013-2016 (consisting of five hospitals with emergency and secondary care facilities and a paediatric 193 
hospital)[14].  . 194 
We found that the impact of the vaccine in primary care was lower than that predicted by Jit et al 195 
(2007), with a substantial proportion of overall reduction in healthcare cost due to a decrease in GP 196 
consultations [11]. Data were available on consultations for diarrhoea, vomiting and all 197 
gastrointestinal illness, however due to possible double counting and for consistency with other data 198 
analysed for this study, we decided only to include the impact from consultations for diarrhoea. This 199 
may therefore represent an underestimate, which may explain the 32% reduction in prescriptions 200 
during the rotavirus season, despite only a 16% reduction in consultations. Lack of adherence to the 201 
use of appropriate Read codes may also help to explain this underestimate. 202 
  
The impact of childhood rotavirus infection and the vaccine on nonmedical costs was not included in 203 
this study, however it is likely that there are significant costs associated with productivity loss (or 204 
“time-off” work) of the parent(s). Different studies give different estimates of the number of work 205 
days lost – typically ranging from around two to five days [15]. The typical UK worker earns a median 206 
daily wage of £103.6 [16]. Hence, 2 days (5 days) forgone work on behalf of the caregiver results in 207 
£207.2 (£518) in lost earnings per childhood rotavirus case. Some estimates suggest that the loss in 208 
productivity to the economy is the difference between a rotavirus vaccination programme being, not 209 
only cost-effective, but cost saving in the UK [17].  210 
This study only considers costs and does not value the improved quality of life which a reduction in 211 
rotavirus incidence would deliver.  Jit and Edmunds (2007) report a quality of life (QALY) loss due to 212 
rotavirus of 0.0022 for a child and 0.00184 for an adult per case of rotavirus [11]. In our study, there 213 
was a mean of 472 laboratory confirmed cases of rotavirus pre-vaccination programme, compared 214 
with 110 cases post- vaccination programme, per 100,000 infants <5 in Scotland. If we use this as a 215 
proxy for the mean number of rotavirus cases pre- and post-vaccination, then we estimate the QALY 216 
loss averted per family (2 adults, 1 infant) as 2.13 QALYs per 100,000 infants <5 years old in Scotland 217 
between the mean year pre-and post-vaccination period. 218 
Since completion of our analysis, the first full year of data became available for calendar year 2015 219 
(infants born Jan-Dec 2014). These indicate 53,013 infants (18,141 infants per 100,000) received 220 
rotavirus vaccine in 2015. This is comparable with the estimate used in our analysis (18,575 infants, 221 
per 100,000). 222 
Strengths and limitations 223 
At time of publication, this is the only study the authors are aware of which attempts to estimate the 224 
cost-impact of the rotavirus vaccination programme for the whole of Scotland, based on observational 225 
data. 226 
  
The challenge with using indicators of gastrointestinal illness such as reporting of symptoms of 227 
diarrhoea as a proxy for rotavirus is that it also captures changes in the prevalence of other 228 
gastrointestinal illnesses unrelated to rotavirus. As a result, there are uncertainties in the estimates of 229 
resource use both pre and post vaccination and these differ depending upon the type of resource-use 230 
considered.  In comparing our results with other studies it is, therefore, important to note the precise 231 
definitions included in the analysis. 232 
We obtained data on the number of prescriptions made per day per patient population, however, we 233 
did not have a further breakdown of composition of these prescriptions (i.e. which hydration drugs 234 
were given). Hence, it was not possible to calculate the change in mean prescriptions and then attach 235 
unit costs. Rather, we calculated the change in the mean gross cost of prescriptions pre-and post-236 
vaccination programme. A detailed breakdown of the prescriptions given would have provided a more 237 
accurate estimate of the cost-impact, however it is not clear whether an absence of this breakdown 238 
suggests an over-or underestimate of the overall cost-impact. The data we obtained was based on 239 
prescriptions for rotavirus in primary care. However, there is the possibility that these prescriptions, 240 
which are mainly rehydration drugs, could have been prescribed for alternative conditions requiring 241 
rehydration.  242 
Due to duplication concerns, it was not possible to use calls relating to vomiting and diarrhoea, 243 
combined, from NHS24 data. Hence, data on calls citing diarrhoea in infants <1 year old and <5 years 244 
old were used as a proxy for rotavirus. It is acknowledged that this is likely to be an underestimate of 245 
the true total cost associated with NHS24.  Similarly, for duplication concerns, only GP consultations 246 
for diarrhoea were included. This is also likely to represent a considerable underestimate of the cost. 247 
The overall cost-impact of the vaccination programme was highly sensitive to the cost of the vaccine, 248 
which we were not able to confirm.  Our analysis relies on an estimate from the literature which we 249 
varied in sensitivity analysis.  250 
  
4. Conclusion 251 
In this study we have estimated the mean change in rotavirus-related resource use before-and-after 252 
the introduction of the Scottish Government’s rotavirus vaccination programme in 2013. In doing so, 253 
we have observed reductions in the burden placed on rotavirus-related; laboratory reports; 254 
hospitalisations; GP consultations; A&E attendances; and NHS24 calls. Our analysis showed a 255 
reduction in the mean number of rotavirus-related hospital bed-days of 40%. This reduction 256 
accounted for 83% of the overall cost reduction associated with the implementation of the rotavirus 257 
vaccination programme. This study found that the overall cost impact of the rotavirus vaccination 258 
programme (that is, the cost of delivering the programme minus the reduction in resource costs) was 259 
£435,000 increase (2013 prices) per annum per 100,000 infants <5 years.  260 
5. Methods 261 
In line with previous research [11] and European Centre for Disease Prevention and Control (ECDC) 262 
[12] guidance, this study adopted a “before and after” approach with the pre-vaccination period 263 
serving as a reference point from which to compare the post-vaccination period.  264 
5.1 Statistical analysis 265 
In line with previous research [18] and European Centre for Disease Prevention and Control (ECDC) 266 
[19] guidance, this study adopted a “before and after” approach with the pre-vaccination period 267 
serving as a reference point from which to compare the post-vaccination period.  268 
This study defined the net cost-impact of the programme as being the cost of the vaccination 269 
programme minus cost savingsreductions in resource use. As such, the net cost-impact was defined 270 
as follows: 271 
Net cost impact = (cost of vaccine + administration payment) – (cost savingreductions from lab reports, 272 
hospitalisations, A&E attendances, GP consultations, prescriptions and NHS24 calls). 273 
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2.1 Sample 274 
To compare the impact of the rotavirus vaccination programme, in terms of the change in resource use 275 
and cost-impact, we used an interrupted time series analysis [20]. 276 
To estimate the overall cost-impact of the rotavirus vaccination programme, we first estimated the 277 
rotavirus-related resource utilisation for each resource pre- and post-vaccination programme, in units 278 
determined by how the data were collected (i.e. resource use per week or per month).  We attached 279 
unit costs to resource use to estimate the cost of this resource over each time period for which the 280 
data were collected.  Mean resource use in the pre-and post-vaccination periods were estimated using 281 
a range of modelling approaches.  We selected a Generalised Linear Model (GLM) with a Poisson family 282 
and log link as this reduced autocorrelation and provided the best model fit. We assessed goodness 283 
of fit of alternative models using the Akaike and Bayesian Information Criteria [21]  Underlying trend 284 
was accounted for within the regression framework and seasonality were modelled by including 285 
Fourier terms (sine and cosine terms) [20] and a dummy variable representing the peak rotavirus 286 
season (January-May). We also included an interaction term between the seasonality variables and 287 
the relevant period variable (week or month) to allow seasonality to vary in different time periods.  288 
We hypothesised that the rotavirus vaccination programme would result in a permanent level change 289 
in resource use [20].  We therefore included a single binary variable to represent the intervention 290 
which was coded ‘0’ in the period prior to the vaccination programme and ‘1’ in the period following 291 
the introduction of the programme.  292 
Population data for all infants <5 years old living in Scotland over the study period were obtained from 293 
appropriate sourcesthe National Records of Scotland and used as the denominator in all 294 
calculations.an offset variable [22]. Incidence rates per 100,000 were calculated as the number of 295 
incidenceincidents (i.e. days in hospital or GP consultations) divided by the study population (number 296 
of childreninfants <5 years old living in Scotland) per year multiplied by 100,000. The same approach 297 
was used to estimate the cost of the programme, hence cost per 100,000 represents the cost of 298 
  
providing the vaccination to eligible babiesinfants (age 8 weeks and again at 12 weeks) to realise the 299 
benefits over the population of all infants <5 years. Mid-year population estimates obtained from the 300 
National Records of Scotland database were used to calculate incidence rates for all resource use [13]. 301 
One-way sensitivity analysis was undertaken to estimate the impact on the cost of the vaccination 302 
programme of alternative vaccine prices. Vaccine price was varied +/-50% of the base case price.. The 303 
results are presented in the appendix. 304 
2.2 5.2 Perspective  305 
This study takes the perspective of the UK National Health Service (NHS) and includes resource use 306 
associated with laboratory reports, hospitalisations, A&E attendances, GP consultations, prescriptions 307 
and NHS24 calls. This is the only study at present to take such a wide perspective in estimation of the 308 
economic benefits from a national rotavirus vaccination programme in Scotland.  309 
2.3 Time horizon for evaluation 310 
To estimate the overall cost-impact of the rotavirus vaccination programme, we calculated the 311 
difference in rotavirus-related resource utilisation between a “mean year” prior to and following the 312 
vaccination programme. However, as rotavirus infection is highly seasonal, calculating the change in 313 
healthcare utilisations over the rotavirus season provides a more accurate estimation of the change 314 
occurring primarily from rotavirus vaccine. This approach helps distinguish the impact of rotavirus 315 
from other gastrointestinal infections such as norovirus, which will feature in the surrogate data 316 
sources such as calls to NHS24 citing diarrhoea and vomiting. The precise occurrence and duration of 317 
the rotavirus season varies between countries [12].  For the purposes of this study, we defined the 318 
rotavirus season as January to April (week 1-18). The years used for each resource were: 2009-2014 319 
for laboratory reports; 2010-2014 for hospitalisations; 2011-2014 for A&E; 2011-2014 for GP 320 
consultations; 2010-2014 for NHS24 calls; and 2010-2014 for prescriptions. For each resource, the pre-321 
vaccination years were used to construct a pre-vaccination mean year to compare with post-322 
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vaccination. Two years of post-vaccination data were used for each resource to calculate the post-323 
vaccination mean year. 324 
In addition to examining annual cost, we also looked at the impact of the programme over the 325 
rotavirus season only.  However, the cost of the programme remains the cost per full year. This is 326 
because, to obtain the benefits we observe over the rotavirus period only, the programme would 327 
still have to be delivered year round. 328 
2.4 Measurement of resource use 329 
5.3 Measurement of resource use 330 
Data available for each resource were; 2009-2014 for laboratory reports; 2010-2014 for 331 
hospitalisations; 2010-2014 for NHS24 calls; 2010-2014 for prescriptions; 2011-2014 for A&E; and 332 
2011-2014 for GP consultations. 333 
2.4.1 5.3.1 Laboratory confirmed reports  334 
All laboratory confirmed cases of rotavirus infection in Scotland are reported to HPS via the Electronic 335 
Communications of Surveillance in Scotland (ECOSS) system [14]. A positive laboratory sample 336 
was[23]. A positive laboratory sample was detected using a real-time PCR and were only counted for 337 
the first sample from any patient episode and repeated laboratory tests for the same episode were 338 
not included in this cost exercise.. Laboratory reports for childreninfants <5 years old in the pre-and 339 
post-vaccination years were used.  340 
2.4.2 5.3.2 Hospitalisation data 341 
All hospitalisations for childreninfants <5 years were extracted using Scottish Morbidity Records 342 
(SMR01) database using predefined International Classification of Diseases 10 (ICD10) codes Rotavirus 343 
enteritis “A080” and Viral enteritis unspecified (possible rotavirus) “A083”, “A084” and “A085” 344 
[15].[24]. This aimed to capture admissions for rotavirus, which are not laboratory confirmed due to 345 
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the relatively short length of stay and which are coded under the more general term of viral enteritis. 346 
Due to concerns of possible double counting of patients only data with the relevant ICD10 code as 347 
main diagnosis were included.  348 
The unit of analysis is an “episode”. When a patient is discharged from hospital or transferred between 349 
hospitals, specialties or to the care of a different consultant, an episode is generated. Episode data 350 
waswere grouped together to identify continuous inpatient stays (CIS) and it is this level of analysis 351 
that was used to monitor hospital admissions and length of stay in this study.  352 
2.4.3 5.3.3 Accident and Emergency (A&E) data 353 
Age specific monthly data on attendances at A&E data for symptoms associated with gastrointestinal 354 
illness was available from Information Services Division (ISD). TheThese data isare based on a 355 
combination of ICD10 codes and, where coding was not used, free text analysis and data. Data were 356 
analysed for childreninfants aged <5 years. 357 
2.4.4 5.3.4 GP consultation data 358 
Data on GP consultations, who provide all primary care for infants in Scotland, recorded for all infants 359 
<5 years old for diarrhoea were obtained as the best proxy for rotavirus-related GP attendances. 360 
Weekly aggregate data are received by HPS from approximately 50% of General Practices (GP) across 361 
Scotland on the number of consultations based on defined Read codes, which are currently the 362 
standard clinical classification terminology system used in GPs in the United Kingdom.  Data on GP 363 
consultations recorded for all children <5 years old for diarrhoea were obtained as the best proxy for 364 
rotavirus-related GP attendances. [25]. Data were obtained from a broad geographical spread of 365 
Scotland and were considered representative of Scotland as a whole. Data were scaled to account for 366 
100% of GP practices.   367 
2.4.5 5.3.5 NHS24 syndromic surveillance data 368 
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HPS monitor trends in calls made to the NHS24 telephone helpline in Scotland. NHS24 is also the route 369 
to out-of-hours general practice care. Data gathered on the number of calls relating to vomiting and 370 
diarrhoea give an indication into the incidence of gastroenteritis in the community. Due to duplication 371 
concerns, it was not possible to use data relating to vomiting and diarrhoea combined. Hence, data 372 
on calls citing diarrhoea in childreninfants <5 years old were used as a proxy for rotavirus. 373 
2.4.6 5.3.6 Prescription data 374 
Data on rotavirus-related drug prescriptions were collected by the Prescribing Information System 375 
(PIS) provided by ISD Scotland. and based on prescriptions administered in the primary care setting. 376 
Treatment for rotavirus typically involves the prescription of oral rehydration drugs. As such, dataData 377 
on prescription of the following drugs, listed in local formularies, were obtained;used as a proxy for 378 
rotavirus and viral enteritis: Dioralyte; Dioralyte Relief; Electrolade; O.R.S Oral, Peach. Data were 379 
provided in terms of the gross ingredient cost (£) per month for infants <5 years old over the period 380 
2010-2015. Hence, change in gross cost pre-and post-vaccination were reported, rather than change 381 
in resource use (i.e. unit costs were not necessary). 382 
2.4.7 Cost of vaccination programme 383 
5.3.7 Vaccine price 384 
The Joint Committee on Vaccination and Immunisation (JCVI) carried out a review of the published 385 
literature on the cost-effectiveness of rotavirus vaccines [16].on behalf of the Scottish Government 386 
[26]. The JCVI statement on rotavirus vaccine assumes a vaccine unit price of £35 per dose (2006 387 
prices). This price is based on the work of Jit & Edmunds [17]. The authors state that the catalogue 388 
price of Rotarix® in the UK is £41.38 (2006 prices). Based on this price, they assume that a single dose 389 
of Rotarix® would be available to the NHS at £35. At the price of £35 per dose, the cost per QALY 390 
gained would be £61,000 and hence unlikely to be considered cost-effective. ), based on the work of 391 
Jit & Edmunds [11]. At the price of £35 per dose, the incremental cost per QALY gained would be 392 
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£61,000 and hence unlikely to be considered cost-effective. Further modelling by the authors 393 
suggested that the vaccine would have to be priced at £19 per dose for the cost of the programme to 394 
be less that £30,000 per QALY gained and hence deemed cost effective., given the current UK 395 
threshold. For this reason, we chose to assume a vaccine price of £19 per dose [17]. Inflating this to 396 
2014 prices equates to £23.91 per dose.[11]. Inflating this to 2014 prices equates to £23.91 per dose 397 
and this was used as our base case price. Due to commercial sensitivities, there is no published price 398 
for the vaccine other than the JCVI statement. 399 
The local health board pay each relevant GP an administrative payment of £7.67 per child receiving 400 
the rotavirus vaccination (one payment for two doses)[18].[27]. This payment was therefore included 401 
as a direct cost of providing the service. 402 
2.4.8 5.3.8 Valuation of resource use  403 
All prices are expressed in 2013/14 prices and have been inflated (where necessary) using the Hospital 404 
and Community Health Services (HCHS) Index which uses an inflation rate specific to the UK health 405 
service (PSSRU, 2014).  406 
Any stool sample taken from an infant suffering from diarrhoea and vomiting would undergo a full 407 
screening for a range of gastrointestinal pathogens, rather than for one specific causative agent.  408 
Hence, the unit cost of a routine enteritis laboratory report was given by Lorgelly et al as £15.08 per 409 
report (in 2001/02 prices, £20.99 in 2013/14 prices) [19].[28].  410 
The unit cost estimate for hospitalisations in 2013/14 was obtained from ISD. Using their new patient-411 
level costing data, they were able to estimate the cost per day of hospital treatment for rotavirus 412 
(based on ICD10 code A080). The unit cost per day for rotavirus was estimated at £920 (2013/14).  This 413 
unit cost is applied to both incidents of rotavirus coded as “rotavirus” and “viral enteritis” in SMR01 414 
hospitalisation data.  415 
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A standard unit cost of £107 per attendance at A&E was obtained from ISD’s annual Scottish Health 416 
Service Costs [20]. 417 
A standard unit cost of £107 per attendance at A&E was obtained from ISD’s annual Scottish Health 418 
Service Costs [29]. 419 
The unit cost of a GP consultation was obtained from the Personal Social Services Research Unit 2014 420 
publication [21].[30]. The unit cost was £37.50, per GP visit lasting 11.7 minutes (excluding 421 
qualification costs). 422 
The unit cost per call to NHS24 was reported by Munro et al as £15 (2001 prices). Inflating this to 2014, 423 
provides a unit cost of £20.88 [22][31]. 424 
DeclarationResults 425 
3.1 Cost of vaccination programme 426 
Based on the actual number of infants who received the vaccine over the evaluation period 1st July-427 
30th September 2013, it was calculated that 18,575 infants received the vaccination in 2013, per 428 
100,000 infants <5 years old living in Scotland (note: the vaccine uptake rate was 92.7% however rates 429 
per 100,000 are calculated over the entire relevant population of infants <5 years old). This figure is 430 
multiplied by the vaccine cost per 2 doses. This equates to a vaccine cost of £888,278 per 100,000 431 
children <5 years old in Scotland in 2013/14. The additional administrative payment made to GPs of 432 
£7.67 per infant (per two doses) equates to £142,474 per 100,000 children <5 years old in Scotland. 433 
Taken together, this indicates that the cost of the vaccination programme was £1,030,751 per 100,000 434 
children <5 years old in Scotland. 435 
Scaling-up the rates per 100,000 infants to the total number of infants we estimate to have received 436 
the vaccination over 2013 (54,664), we estimate a total annual vaccine cost of £2,614,032 per year. 437 
The total annual estimated cost of GP administration payments for this period, for these uptake 438 
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figures, was £419,273 per year. Taken together, this suggests a total vaccination cost of £3,033,305 439 
for the entire population of eligible infants in Scotland in 2013. This represents the absolute cost outlay 440 
for the vaccination programme, rather than the cost per 100,000 infants. 441 
Table 1 shows the reduction in rotavirus-related resource use associated with children less than 5 442 
years old for the mean year pre- and post-vaccination programme.  443 
[TABLE 1] 444 
Table 2 shows the reduction in rotavirus-related resource use associated with children less than 5 445 
years old for the mean rotavirus season pre- and post-vaccination programme.  446 
[TABLE 2] 447 
Table 3 shows the overall cost-impact of the rotavirus vaccination programme. Three separate 448 
results are given: the change in absolute (total) annual cost between the pre- and post-vaccination 449 
period, the change in the annual pre-and post-vaccination period cost per 100,000 infants, the 450 
change in cost pre-and post-vaccination period per 100,000 infants over the rotavirus season only. 451 
[TABLE 3] 452 
Figure 1 shows that 85% of the cost savings associated with reduced incidence of rotavirus over the 453 
mean rotavirus season (Jan-Apr) between 2009-2015 was due to the reduction in hospital bed-days. 454 
[FIGURE 1] 455 
Figure 2 gives the estimate of the cost reduction for rotavirus-related resource use for the mean 456 
year on an annual and rotavirus season basis. Figure 2 shows that almost all (95%) of the cost 457 
reduction for the mean year was accrued over the rotavirus season (Jan-Apr) alone. 458 
[FIGURE 2] 459 
2.Discussion 460 
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Prior to the introduction of the rotavirus vaccination programme, the Scottish Government predicted 461 
that such a programme could reduce the number of rotavirus-related hospital stays by approximately 462 
70% [23]. Indeed Forrest (2017) found a reduction of 85% and 91% in rotavirus related admissions and 463 
bed days, respectively, in a paediatric hospital setting in Lothian, Scotland [24]. Our analysis showed 464 
a reduction in the mean number of rotavirus-related hospital admissions and bed-days of 51% and 465 
59%, respectively, over the rotavirus season. In undertaking this study, we gave much consideration 466 
to the issue of how best to capture the impact of rotavirus on hospital resources. When we considered 467 
the changes in solely those hospital admissions and bed-days which were coded for rotavirus specific 468 
(1st and 2nd diagnostic position), we observed a reduction in hospital admissions for rotavirus and 469 
rotavirus-related hospital stays of 68% and 73%, respectively. However, it became clear that there are 470 
many hospital admissions relating to rotavirus which are simply coded as generic viral enteritis. Hence, 471 
we decided that to not include viral enteritis in our analysis would mean underestimating the true 472 
burden of rotavirus. As a result, we chose to include rotavirus specific and viral enteritis specific (both 473 
1st diagnostic position) as our best estimate of the burden of rotavirus in the hospital setting. However, 474 
as the total number of conditions included in our analysis has increased, the percentage change 475 
between the pre-and post-vaccination group will not be as large.  476 
Additionally a paper by Hsu (2005) suggests that there is low sensitivity with the use of ICD codes to 477 
capture the burden of rotavirus on hospitalisations [25]. Their findings suggest that current estimates 478 
of rotavirus-related hospitalisations based on ICD codes may substantially underestimate the true 479 
burden of rotavirus on hospitalisation admissions.  480 
We found that the impact of the vaccine in primary care was lower than that predicted by Jit et al with 481 
a substantial proportion of overall reduction in healthcare cost due to a decrease in GP consultations 482 
[17].  Data were available on consultations for diarrhoea, vomiting and all gastrointestinal illness, 483 
however due to possible double counting and for consistency with other data analysed for this study, 484 
we decided only to include the impact from.  consultations for diarrhoea. This may therefore represent 485 
  
an underestimate, which may explain the 32% reduction in prescriptions during the rotavirus season, 486 
despite only a 16% reduction in consultations. Lack of adherence to the use of appropriate Read codes 487 
may also help to explain this underestimate. 488 
The impact of childhood rotavirus infection and the vaccine on nonmedical costs was not included in 489 
this study, however it is likely that there are significant costs associated with productivity loss (or 490 
“time-off” work) of the parent(s). Different studies give different estimates of the number of work 491 
days lost – typically ranging from around two to five days [26]. The typical UK worker earns a median 492 
daily wage of £103.6 [27]. Hence, 2 days (5 days) forgone work on behalf of the caregiver results in 493 
£207.2 (£518) in lost earnings per childhood rotavirus case. Some estimates suggest that the loss in 494 
productivity to the economy is the difference between a rotavirus vaccination programme being, not 495 
only cost-effective, but cost saving in the UK [28].  496 
This cost-impact analysis did not quantify the health related quality of life (HRQoL) gains associated 497 
with the vaccination programme, and as such represents an underestimation of the overall benefits 498 
of this programme [2].  499 
Strengths and limitations 500 
At time of publication, this is the only study the authors are aware of which attempts to estimate the 501 
cost-impact of the rotavirus vaccination programme for the whole of Scotland, based on observational 502 
data. 503 
This study examined the cost impact of the introduction of the vaccine over two years post-504 
vaccination, which is important since a common finding of other related studies is that there are 505 
further significant reductions in resource use in the second year after rotavirus vaccination [1, 29]. A 506 
seasonal trend was evident in all data sources examined prior to the introduction of the vaccine and 507 
absent in the two years’ post-vaccine.   508 
  
The challenge with using indicators of gastrointestinal illness such as reporting of symptoms of 509 
diarrhoea as a proxy for rotavirus is that it also captures changes in the prevalence of other 510 
gastrointestinal illnesses unrelated to rotavirus. As a result, a reduction in rotavirus one year may be 511 
cancelled-out by an unrelated increase in norovirus the same year, leaving the all-cause 512 
gastrointestinal illness data unchanged. This would result in the change in rotavirus not being 513 
adequately captured by the data. While this can be accounted to an extent for by examining the 514 
“rotavirus season” it cannot completely rule this out as there could be an overlap in circulation of 515 
gastrointestinal pathogens. There are also several limitations with the A&E data such as: differences 516 
in recording between health boards, the use of ICD10 codes; free text; and a combination of both. This 517 
can also change over time as boards are being encouraged to move towards using ICD10 codes to help 518 
standardise data recording. Despite these limitations, it was decided that the inclusion of this data 519 
would be more informative than its exclusion. 520 
We obtained data on the number of prescriptions made per day per patient population, however, we 521 
did not have a further breakdown of composition of these prescriptions (i.e. which hydration drugs 522 
were given). Hence, it was not possible to calculate the change in mean prescriptions and then attach 523 
unit costs. Rather, we calculated the change in the mean gross cost of prescriptions pre-and post-524 
vaccination programme. A detailed breakdown of the prescriptions given would have provided a more 525 
accurate estimate of the cost-impact, however it is not clear whether an absence of this breakdown 526 
suggests an over-or underestimate of the overall cost-impact. 527 
Due to duplication concerns, it was not possible to use calls relating to vomiting and diarrhoea, 528 
combined, from NHS24 data. Hence, data on calls citing diarrhoea in children <1 year old and <5 years 529 
old were used as a proxy for rotavirus. It is acknowledged that this is likely to be an underestimate of 530 
the true total cost associated with NHS24.  Similarly, for duplication concerns, only GP consultations 531 
for diarrhoea were included. This is also likely to represent a considerable underestimate of the cost.  532 
3.Conclusion 533 
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In this study we have estimated the mean change in rotavirus-related resource use before-and-after 534 
the introduction of the Scottish Government’s rotavirus vaccination programme in 2013. In doing so, 535 
we have observed reductions in the burden placed on rotavirus-related; laboratory reports; 536 
hospitalisations; GP consultations; A&E attendances; and NHS24 calls. Our analysis showed a 537 
reduction in the mean number of rotavirus-related hospital admissions and bed-days of 51% and 538 
59%, respectively, over the rotavirus season. This reduction accounted for 90% of the overall cost 539 
reduction associated with the implementation of the rotavirus vaccination programme. This study 540 
found that the overall cost impact of the rotavirus vaccination programme (that is, the cost of 541 
delivering the programme minus the reduction in resource costs) was £633,499 (2013 prices) per 542 
mean year. Considering only the rotavirus season, we find the total cost impact of the vaccination 543 
programme to be £653,354 per mean year. 544 
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1. Unit costs used in the study 
 
[INSERT TABLE 4] 
 
2. Graphs for changes in additional resource use categories 
 
Figure 3: Accident and emergency attendances (weekly rates per 100,000), for infants <5 
years old in Scotland – 2011 to 2014. 
 
[INSERT FIGURE 3] 
 
Notes: R2=0.72. Dashed line represents introduction of vaccination programme 
Figure 4: GP visits (weekly rates per 100,000), for infants <5 years old in Scotland – 2011 to 
2014. 
 
[INSERT FIGURE 4] 
 
Notes: R2=0.65. Dashed line represents introduction of vaccination programme 
Figure 5: NHS 24 calls (weekly rates per 100,000), for infants <5 years old in Scotland – 2010 
to 2015. 
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Notes: R2=0.59. Dashed line represents introduction of vaccination programme 
Figure 6: Prescriptions costs (monthly rates per 100,000), for infants <5 years old in Scotland 
– 2010 to 2015. 
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Notes: R2=0.71. Dashed line represents introduction of vaccination programme 
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Response to reviewers’ comments 
By Robert Heggie 2/10/18 
Thank you to the editor and reviewers for their comments. We have undertaken substantial 
revisions to our paper, including a complete revision of the statistical analysis (which is now 
modelled as an interrupted time series analysis). We hope very much that you will be pleased with 
our revised paper. 
Editor’s comments 
 
1. Move the Methods section after the Discussion in conformity to the style of this journal. 
Reply: Text has been amended. 
 
2. Add Figure legends to the manuscript DOC after the References. 
Reply: Text has been amended. 
 
Reviewers' Comments 
 
1. To further enrich the discussion section , add a paragraph that compares this cost analysis with a 
recent published paper on a cost-analysis conducted in an Italian Region (Sicily):  
Costantino C, Restivo V, Tramuto F, Casuccio A, Vitale F. Universal rotavirus vaccination program in 
Sicily: Reduction in health burden and cost despite low vaccination coverage. Hum Vaccin 
Immunother. 2018 May 14:1-6. 
https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1471306  
Reply: I have added this reference to the discussion. 
 
2. Line 108 This descriptive study aims to describe difference of resource utilization between pre- 
and post-vaccine period. Contrary to what the authors answered to the previous comment, there 
was a hypothesis of non-equality that was to be shown. This hypothesis was different to show  a 
causality "causality between the vaccination program and resource use reduction". According to this, 
the study needs a statistical test to show a non-equality between pre and post vaccination period 
due to several interventions as shown in the study mentioned by the same authors of Rosemary et al 
(2014) in which the statistical section stated "Rather, we are presenting a descriptive analysis of the 
estimated mean resource use before and after the vaccination programme. Means and medians 
were compared for continuous data and proportions for categorical data. P <0.05 was  considered as 
statistically significant."  
The authors need to conduct a more appropriate statistical analysis. 
Reply: We have redone the statistical analysis as an interrupted time series analysis and look forward 
to receiving your views on this approach. 
 
3. Lines 122-8. To the question on the reference about use of only 1st diagnostic position code to 
estimate the burden of RV in hospital setting, the authors answered that "Unfortunately, there are 
no references or guidance for what is most appropriate in this situation. We made this choice as our 
best attempt to trade-off the risk of double counting (i.e. if we had included rotavirus or viral 
enteritis in 2nd diagnostic position) against the risk of not capturing the true burden." Contrary to 
the authors' opinion, several references implement estimation using all diagnostic position to 
Response to reviewers
increase sensibility of the estimation as reported by Restivo et al (2017) 
https://www.tandfonline.com/doi/full/10.1080/21645515.2017.1264784 
Address this point in the manuscript.  
Reply: Thank you for directing us towards the Restivo (2017) study which we were not aware of. We 
have compared the approach taken in their study with our own and we chose to adopt a more 
restricted definition of rotavirus.  
We selected Rotavirus specific (ICD-10 code: A080) and Viral enteritis unspecified (possible rotavirus) 
(ICD-10 code: A084), appearing in either first or second diagnostic position and based on hospital 
discharge codes, reported in Scottish Morbidity Records (SMR01). This was based on advice from our 
clinical colleagues as these are the only two which either explicitly state that rotavirus was present or 
that it was possibly present. The inclusion of additional ICD-10 codes would likely increase the 
sensitivity of our analysis at the cost of reducing the specificity, i.e. we would increase the number of 
rotavirus cases detected at the cost of increasing the number of non-rotavirus cases included. We 
make it clear which ICD-10 codes are included and excluded to assist the reader and trust that this 
approach will be acceptable.  
 
4. Lines 134-7. Are there data on attendance at A&E without ICD-10 codes.? Its it not a standardized 
procedure? What is the methodology of free text analysis? Which words were included?  Can the 
authors quantify the amount of records without ICD.10 codes? 
Address these issues in the text. 
RH: These data are routinely captured by Information Service Division (ISD) Scotland and accessed by 
Health Protection Scotland (both part of NHS Scotland) for monitoring purposes. As A&E data on 
Scotland were not yet collected in a standard form during the study period this was the most reliable 
data available to us. This has been clearly stated in the text and included in the limitations in our 
discussion section.   
 
5. Lines 139-43 did not address the following question: How many (number not percentage) children 
<5 years old were in charge of pediatrician recruited in the study compared to all Scottish children 
<5 years old? Have they the same demographics characteristics (sex and age) to evaluate 
generalizability of data to all Scottish children? 
Reply: In Scotland, the health system is a unified national service, free at point of care, with no 
private paediatrician provision.  Care of children who are ill is within primary care by a general 
practitioner, and then by a paediatrician within secondary and tertiary care for more acute/severe 
illness. As ours is a retrospective study which covers the whole population of infants in Scotland <5 
years old, there are no issues relating to generalisability in relation to demographic characteristics 
across Scotland.  
 
6. Lines 155-60. The authors are contradicting themselves because of the answer to the lack of data 
on prescription used as a proxy for rotavirus and viral enteritis: "However, we would argue that since 
are as estimating the change in resource use before and after the vaccination programme, is it likely 
the difference is prescribing trends is a results of rotavirus (which was reduced by vaccine) rather 
than other conditions which would not have been expected to change over this period." but in the 
following comment the authors write that "The purpose of our study was not to determine causality 
between the vaccination programme and resource use reduction". The authors had to delete 
prescription analysis not supported by references. 
RH: Thank you for pointing out the inconsistency here, this has been addressed in the text. We have 
retained our analysis on prescription costs as we have data for this period covering drugs prescribed 
specifically for rotavirus. 
 
7. Lines 207-12 
a. The authors need to rewrite the period of results in a more neutral way, reporting value of 
percentages with respective P value of difference and 95% confidence interval.  
b. Avoid words such as "the greatest reduction" that can be used more appropriately in the 
Discussion section. 
RH: This has been addressed in the text. 
 
8. Lines 124-5 
a. The authors should not include viral enteritis unspecified codes from the analysis because as they 
answered, there are no references on this methodology "This is simply the result of conversations 
with those stakeholders involved in the treatment of rotavirus."  
b. To avoid double counting, use an identification code. 
 
Reply: Further to our comment above (comment 3), we included i) Rotavirus specific and iii) Viral 
enteritis unspecified (possible rotavirus) in our analysis on the advice of clinical colleagues and coding 
specialists. 
 
9. Lines 222-225 
a. Avoid placing in the Results section the footnotes of Table 2 (Results are reported in terms of the 
cost of the program, the monetary value or reduction in resource use pre-and post-vaccination 
period, and the difference between the cost of the program and the value of the reduction in 
resource use is estimated as the overall cost-impact of the program). 
b. Rewrite the heading of Table 2 in a more understandable way.  
Reply: Tables have been completed amended. 
 
10. Lines 226-9 
a. Rewrite the period of result reporting value of percentages with respective P value of difference 
and 95% confidence interval.  
b. Move the sentence "This is because, even though the reduction in resource use is observed over 
the rotavirus season, year-round vaccination is required to achieve these reductions" to the 
Discussion section. 
Reply: Results section has been completely redrafted. “Rotavirus season” is no longer included as a 
separate analysis but is instead modelled as part of the interrupted time series analysis. 
 
11. Lines 346-49 
a. Avoid to place here footnotes of Table 3 (which presents the results based on a 50% increase or 
reduction from the price given in the base case)/  
b. Rewrite the period in a more neutral way, reporting  the value of percentages with respective P 
value of difference and 95% confidence interval.  
c. Place this period in the Results section instead of the Appendix. 
Reply: Results section has been completely redrafted. 
 
12. Line 350. Use vaccine cost available on technical schedule. 
 
Reply: In the UK, there is not a technical schedule.  The vaccine is procured nationally, and the costs 
are not shared, even with national public health organisations, such as health protection Scotland.  
Only a few people in government working in procurement are privy to this information.  
 
13. Table 1 
a. Implement the Table with a column reporting p-value of "% Change in resource use" with 95% 
Confidence interval.  
b. able 1 also should have an exhaustive caption instead of "Result" and footnotes with clarification 
of the season period.  
c. The authors try to explain the use of length of hospital stay instead of more appropriate HRG due 
to a lack of update HRG price since 2011/12. But if the cost-analysis has to be coherent with real life 
of Scotland, report HRG price of 2011/12 to show the urgency of update these HRG cost.  
d. Add a reference to clarify methods used by Information Service Division Scotland to built up the 
cost per day spent in hospital due to Rotavirus? Which variables did they include in this parameter? 
Reply: Tables have been completed amended (comment a, b). We obtained an up-to-date cost of the 
cost per day spent in hospital due to rotavirus. This cost has been developed by the Information 
Division Scotland (ISD) who are responsible for capturing health resource data for Scotland. Details 
on the methodology of the cost per day for rotavirus estimate will be included within the appendix as 
supplementary material. This cost is likely to be more appropriate to the Scottish setting than HRG 
costs based on England and Wales (comment c, d). 
 
14. RH: HRGs (rather than DRGs) are used in the UK. However, Scotland does not have the level of 
HRG costing that exists in England. Furthermore, Scottish HRG costs were last updated in 2011/12. 
We obtained the cost per day spent in hospital due to rotavirus directly from the Information Service 
Division Scotland (part of NHS Scotland). They described this as their best estimate of the cost of a 
day spent in hospital in Scotland due to rotavirus in 2013/14. 
Revise accordingly. 
Reply: Please see response to comment 13c and d. 
 
15. Tables 2 and 3 
a. Implement the table reporting p-value of the analysis with 95% Confidence interval. 
b. This Table should have an exhaustive caption and headings. 
 
Reply: Tables have been amended in line with new analysis. 
 
16. Place Table 5 in the Methods section. 
Reply: Tables have been amended in line with new analysis. 
 
Additional comment from RH: In the previous version we had considered a pre-vaccination mean in 
which the starting year for all resources were equal (i.e. 2011). We have removed this scenario as we 
want to ensure we use all data available. This is particular important to maintain statistical power in 
time series analysis.. 
Table 1: Estimated annual cost-impact of the Rotavirus vaccination programme introduced in Scotland in July 
2013 (per 100,000 infants under 5 years)  
 Cost of vaccination 
programme 
Cost reduction from 
vaccination 
programme 
Overall cost-impact 
Overall cost-impact 
(annual) 
£1,030,751 £595,470 £435,281 
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Table 2: Sensitivity analysis of alternative vaccine price on overall cost-impact results 
Test cost (per dose) £11.96 £23.91 (base case) £35.87 
Overall cost-impact 
(annual) 
£586,798 £1,030,751 £1,475,076 
 
Table2
 
Table 3: Adjust incidence rate ratios (IRRs) for the association between vaccination and 
rotavirus-related annual events and costs, for infants <5 years old in Scotland 
 Effects Pre-vaccination 
mean events 
Post-vaccination 
mean events 
Incident rate ratio for association (IRR) between 
introduction of vaccination and resource use 
(IRR 95% CIs) (p-value) 
Laboratory 
reports 
515 
 
105 
 
0.273 (0.266, 0.279), p<0.001 
Hospitalisation 
days (length of 
stay) 
1,169 631 0.599 (0.589, 0.601), p<0.001 
A&E visits 2,177 1,791 
 
0.655 (0.652, 0.658), p<0.001 
GP consultation 3,301  2,672 0.736 (0.729, 0.743), p<0.001 
NHS24 calls 2,725 2,208 0.826 (0.820, 0.833), p<0.001 
Prescriptions N/A N/A 0.798 (0.788, 0.808), p<0.001  
Costs Pre-vaccination 
mean cost 
Post-vaccination 
mean cost 
Cost difference 
Laboratory 
reports 
£10,825 £2,211 £8,615 
Hospitalisation 
days (length of 
stay) 
£1,075,510 £580,624 £494,886 
A&E visits £232,973 £191,662 £41,311 
GP consultation £119,653 
 
£96,871 £22,782 
NHS24 calls £56,913 £46,113 £10,800 
Prescriptions £71,117 £54,041 
 
£17,076 
 
Total costs 1,566,992   £971,522 £595,470 
 
Table3
Table 4: Unit costs attached to resource use in the study 
Resource Unit cost 2013/14 
prices 
Unit cost at source 
year 
Source year Source 
Cost of vaccine (per 
dose) 
£23.91 £19 2004 Jit & Edmunds (2007) 
and JCVI Statement 
Incentive payment to GP £7.67 £7.67 2013/14 GMS Statement of 
financial entitlements 
Laboratory costs (per 
test) 
£20.99 £15.08 2001/02 Lorgelly (2007) 
GP consultation (per 
visit) 
£36.25 £28.81 2004 Unit Costs of Health 
and Social Care 2004 
(PSSRU) 
NHS 24 Syndromic 
Surveillance (per call) 
£20.88 £15 2001 Munro et al (2001) 
Hospitalisations (per 
day) 
£920 £920 2014 ISD 
Attendances at A&E (per 
attendance) 
£107 £107 2014 ISD Scotland Cost 
Book 2014 
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